Toronto Retina Institute

Toronto, Ontario M3C0G9

1 studies enrolling now · 12 studies all time

What they study most

Age - Related Macular Degeneration (AMD), Diabetic Macular Edema, Geographic Atrophy (GA), Macular Degeneration, Neovascular Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration (nAMD), Thyroid Eye Disease, Wet Macular Degeneration

Studies at this site

• Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD — Recruiting now
• A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration — Running, not enrolling
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease — Running, not enrolling
• A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema — Completed
• Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial — Running, not enrolling
• A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema — Completed
• A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration — Completed
• A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema — Completed
• Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye — Completed
• A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA) — Completed
• A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema — Completed
• Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration — Completed